Sridhar Duvvuri
Overview
Explore the profile of Sridhar Duvvuri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marin T, Belov V, Chemli Y, Ouyang J, Najmaoui Y, El Fakhri G, et al.
IEEE Trans Biomed Eng
. 2024 Oct;
72(3):1057-1066.
PMID: 39446540
Objective: In this work, we evaluate a novel joint direct parametric reconstruction framework to directly estimate distributions of RO and other kinetic parameters in the brain from a pair of...
2.
Belov V, Guehl N, Duvvuri S, Iredale P, Moon S, Dhaynaut M, et al.
J Cereb Blood Flow Metab
. 2024 Mar;
44(8):1329-1342.
PMID: 38477292
Stimulation of the M muscarinic acetylcholine receptor reduces striatal hyperdopaminergia, suggesting its potential as a therapeutic target for schizophrenia. Emraclidine (CVL-231) is a novel, highly selective, positive allosteric modulator (PAM)...
3.
Isaacson S, Hauser R, Pahwa R, Gray D, Duvvuri S
Clin Park Relat Disord
. 2023 Jul;
9:100212.
PMID: 37497384
Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson's disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and...
4.
Lewis M, Van Scoy L, De Jesus S, Hakun J, Eslinger P, Fernandez-Mendoza J, et al.
Biomolecules
. 2023 May;
13(5).
PMID: 37238699
Current pharmacotherapy has limited efficacy and/or intolerable side effects in late-stage Parkinson's disease (LsPD) patients whose daily life depends primarily on caregivers and palliative care. Clinical metrics inadequately gauge efficacy...
5.
Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S
CNS Neurol Disord Drug Targets
. 2023 Mar;
23(4):476-487.
PMID: 36999711
Currently, available therapeutics for the treatment of Parkinson's disease (PD) fail to provide sustained and predictable relief from motor symptoms without significant risk of adverse events (AEs). While dopaminergic agents,...
6.
Krystal J, Kane J, Correll C, Walling D, Leoni M, Duvvuri S, et al.
Lancet
. 2022 Dec;
400(10369):2210-2220.
PMID: 36528376
Background: Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive allosteric modulator in development for the treatment of schizophrenia. We aimed to evaluate the safety and tolerability of multiple...
7.
Sasane R, Bartels A, Field M, Sierra M, Duvvuri S, Gray D, et al.
J Clin Invest
. 2021 Apr;
131(11).
PMID: 33822767
BACKGROUNDRecently the α1 adrenergic receptor antagonist terazosin was shown to activate PGK1, a possible target for the mitochondrial deficits in Parkinson disease related to its function as the initial enzyme...
8.
Huang X, Lewis M, Jodi Van Scoy L, De Jesus S, Eslinger P, Arnold A, et al.
J Parkinsons Dis
. 2020 Sep;
10(4):1515-1527.
PMID: 32986682
Background: Current drug treatments have little efficacy in advanced-to-end-stage Parkinson's disease (advPD), yet there are no reports of interventional trials in advPD. D1 dopamine agonists have the potential to provide...
9.
PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial
Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray D
Ther Adv Neurol Disord
. 2020 Mar;
13:1756286420911296.
PMID: 32201505
Background: PF-06649751 is a novel, oral, non-catechol-based, D1/D5 dopamine receptor partial agonist under investigation for the treatment of motor symptoms associated with Parkinson's disease. Methods: A 15-week, phase II, double-blind,...
10.
Balice-Gordon R, Honey G, Chatham C, Arce E, Duvvuri S, Naylor M, et al.
Int J Neuropsychopharmacol
. 2020 Feb;
23(5):287-299.
PMID: 32055822
Background: Dopamine D1 receptor signaling plays key roles in core domains of neural function, including cognition and reward processing; however, many questions remain about the functions of circuits modulated by...